All In Biotech

Free tool

FAERS Monitor: Tezruly

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218139 or its brand name (Tezruly, Terazosin Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

7,627

Serious

5,231

69% of reports

Hospitalization

2,734

Death reported

857

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective489
  • fatigue478
  • diarrhoea402
  • dizziness397
  • dyspnoea395
  • asthenia367
  • acute kidney injury357
  • death344
  • chronic kidney disease320
  • off label use315
  • renal failure303
  • nausea296
  • fall288
  • pain274
  • pneumonia261

Reports by year received

View as table
YearReports
20049
2005235
200652
200711
200815
200945
201035
2011138
2012190
2013417
2014517
2015754
2016751
2017703
2018686
2019674
2020549
2021484
2022353
2023323
2024251
2025259
2026175

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,532 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic kidney diseaseSignal32011.710.53,106
acute kidney injurySignal3576.45.81,645
renal failureSignal3036.35.61,352
astheniaSignal3672.72.4396
fallSignal2882.42.1234
pneumoniaSignal2612.22.0177
dizzinessSignal3972.22.0263
dyspnoea3951.91.7179
diarrhoea4021.71.6124
fatigue4781.71.6140
pain2741.21.112
death3441.11.03
nausea2961.00.90
drug ineffective4891.00.90
off label use3151.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.